References
- Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526–536.
- Burke KE, Lamont JT. Clostridium difficile infection: a worldwide disease. Gut Liver. 2014;8(1):1–6.
- Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247–263.
- Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–1548.
- Hasegawa M, Yamazaki T, Kamada N, et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J Immunol. 2011;186(8):4872–4880.
- Koon HW, Ho S, Hing T, et al. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrob Agents Chemother. 2014;58(8):4642–4650.
- Girinathan BP, Braun S, Sirigireddy AR, et al. Importance of glutamate dehydrogenase (GDH) in Clostridium difficile colonization in vivo. PLOS One. 2016;11(7):e0160107.
- Czuprynski CJ, Johnson WJ, Balish E, et al. Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun. 1983;39:1368–1376.
- Peng Z, Ling L, Stratton CW, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):15
- Fekety R, Silva J, Toshniwal R, et al. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis.1979;1(2):386–397.
- Knoop FC. Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin. Infect Immun. 1979;23(1):31–33.
- Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–499.
- Wilson KH, Sheagren JN, Freter R, et al. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis. 1986;153(3):547–551.
- Chen X, Katchar k, Goldsmith J, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984–1992.
- Sodhi C, Richardson W, Gribar S, Hackam DJ. The development of animal models for the study of necrotizing enterocolitis. Dis Models Mech. 2008;1(2–3):94–98.
- Collins J, Auchtung JM, Schaefer L, Eaton KA, Britton RA. Humanized microbiota mice as a model of recurrent Clostridium difficile disease . Microbiome. 2015;3:35.
- Julia V, McSorley SS, Malherbe L, et al. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with Leishmania major. J Immunol. 2000;165(10):5637–5645.
- Hutton ML, Mackin KE, Chakravorty A, Lyras D. Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett. 2014;352(2):140–149.
- Riegler G, Esposito I. Bristol scale stool form. a still valid help in medical practice and clinical research. Tech Coloproctol. 2001;5:163–164.
- Schnitt SJ, Antonioli DA, Goldman H. Massive mural edema in severe pseudomembranous colitis. Arch Pathol Lab Med. 1983;107(4):211–213.
- Tonna I, Welsby PD. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J. 2005;81(956):367–369.
- Farooq PD, Urrunaga NH, Tang DM, von Rosenvinge EC. Pseudomembranous colitis. Dis Mon. 2015;61(5):181–206.
- Sugiyama T, Mukai M, Yamashita R, et al. Experimental models of Clostridium difficile enterocolitis in gnotobiotic mice. Prog Clin Biol Res. 1985;181:203–206.
- Kelly CP, Pothoulakis C, Vavva F, et al. Neutrophil recruitment in Clostridium difficile toxins. Antimicrob Agents Chemother. 1996;40(2):373–379.
- Abrams GD, Allo M, Rifkin GD, et al. Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut. 1980;21(6):493–499.